Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other fibronectin-binding integrins refers to a diverse group of heterodimeric cell surface receptors, excluding the primary fibronectin receptor alpha-5-beta-1, that mediate cellular interactions with the extracellular matrix protein fibronectin (NIH, PubMed). This group primarily includes members of the alpha-v subfamily (alpha-v-beta-1, alpha-v-beta-3, alpha-v-beta-5, alpha-v-beta-6, and alpha-v-beta-8) as well as alpha-4-beta-1, alpha-8-beta-1, alpha-9-beta-1, and the platelet-specific alpha-IIb-beta-3 (NIH, Reactome). These receptors typically recognize the Arg-Gly-Asp (RGD) tripeptide motif or the Leu-Asp-Val (LDV) motif within fibronectin to regulate essential processes like cell adhesion, migration, and survival (Wikipedia, NIH). In pathological contexts, these integrins are heavily implicated in tumor angiogenesis, cancer metastasis, and the activation of latent TGF-beta, which drives tissue fibrosis (Frontiers, PubMed). Consequently, they have been the focus of numerous therapeutic strategies, including monoclonal antibodies and small-molecule antagonists, aimed at treating oncology, inflammatory diseases, and fibrotic disorders (NIH, PubMed).
Competitive antagonism of the ligand-binding pocket (specifically the RGD or LDV recognition sites), which prevents the integrin from interacting with fibronectin and other extracellular matrix proteins, thereby blocking adhesion-dependent signaling and the mechanical activation of latent TGF-beta (NIH, PubMed).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other fibronectin-binding integrins.